Lucid Diagnostics Inc. (LUCD)
- Previous Close
0.7794 - Open
0.7750 - Bid 0.7728 x 100
- Ask 0.8000 x 100
- Day's Range
0.7700 - 0.7909 - 52 Week Range
0.6300 - 1.5800 - Volume
209,057 - Avg. Volume
176,846 - Market Cap (intraday)
39.027M - Beta (5Y Monthly) 1.47
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2100 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.71
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
www.luciddx.comRecent News: LUCD
View More
Performance Overview: LUCD
Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LUCD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LUCD
View MoreValuation Measures
Market Cap
38.45M
Enterprise Value
83.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.10
Price/Book (mrq)
--
Enterprise Value/Revenue
22.02
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-72.72%
Return on Equity (ttm)
-300.52%
Revenue (ttm)
3.8M
Net Income Avi to Common (ttm)
-54.15M
Diluted EPS (ttm)
-1.2100
Balance Sheet and Cash Flow
Total Cash (mrq)
26.27M
Total Debt/Equity (mrq)
89.10%
Levered Free Cash Flow (ttm)
-33.01M
Research Analysis: LUCD
View MoreCompany Insights: LUCD
LUCD does not have Company Insights